|Description||AM-1220 is a selective cannabinoid receptor CB1 agonist , with about 19x selectivity for CB1 over the related CB2 receptor originated by Sterling Winthrop. In October 2015 AM-1220 is a controlled substance in China. AM-1220 was first detected as an ingredient of synthetic cannabis smoking blends in 2010.|
|Solubility||Soluble in DMSO|
|Application||an ingredient of synthetic cannabis smoking blends|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Sterling Winthrop|
MDA 19, a benzohydrazide derivative, has been found to be a CB2 receptor agonist and could be useful in reducting the Attenuates tactile allodynia of rats. IC50...
AM 1714, a synthetic cannabimimetic indole derivative, is a potent and selective agonist for the cannabinoid receptor.
A-836339 is a synthetic and potent cannabinoid receptor full agonist. It displays a higher affinity for the peripheral CB2 receptor with Ki value of 0.64 nM ove...
CB-13 is a dual agonist of the CB1 (IC50 = 15 nM) and CB2 (IC50 = 98 nM) receptors, displays antihyperalgesic activity in a rat model of neuropathic pain with n...
Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane.
Iodopravadoline, also known as AM630, is an inverse agonist at the human cannabinoid CB1 receptor. Iodopravadoline has been found to attenuate the ability of a ...
Taranabant is a cannabinoid 1 receptor inverse agonist ( IC50 =0.3 nM).
Drinabant is a highly potent, selective antagonist for the CB1 receptor with Ki values of 0.16-0.44 nM.
BML-190 is a selective cannabinoid CB2 receptor inverse agonist with Ki of 435 nM, with 50-fold selectivity over CB1 receptor.
Otenabant, also known as CP-945,598, is a drug which acts as a potent and highly selective CB1 antagonist. It was developed by Pfizer for the treatment of obesi...
AM 2232, a synthetic cannabimimetic indole derivative, is a potent and selective agonist for the cannabinoid receptor, with Ki values of 0.28 and 1.48 nM for th...
Rimonabant Hydrochloride, used as a tool to investigate CB receptor properties, it is a selective antagonist of cannabinoid CB1 receptor (Ki = 1.98 nM) and inve...
CB1-IN-1 is an antagonist of cannabinoid receptor type 1 (CB1R) located in the peripheral nervous system, which may be significant for pain modulation.
L-768242, an indole derivative, has been found to be a CB2 receptor agonist and was once studied to exhibit anti-nociceptive and antihyperalgesic activities in ...
AM 1235, a synthetic cannabimimetic indole derivative, is a potent and selective agonist for the cannabinoid receptor, with Ki values of 1.5 and 20.4 nM for the...
AM251 block the inhibitory effects of endocannabinoids and synthetic cannabinoid agonists on transmitter release through an action at presynaptic cannabinoid 1 ...
Rosonabant is a CB1 receptor antagonist/inverse agonist originated by Esteve. It is an appetite suppressant for the treatment of obesity. But development of the...
WIN 55212-2 mesylate
The mesylate salt form of WIN 55212-2, an aminoalkylindole derivative, is a CB receptor agonist and could be effective against some inflammatory reponse. IC50: ...
Levonantrado is a synthetic cannabinoid analog of dronabinol developed by Pfizer in the 1980s. Levonantrado is around 30x more potent than THC, and exhibits ant...
BAY 38-7271, also called as KN 38-7271, is a cannabinoid receptor agonist with analgesic and neuroprotective effects. The doses of BAY 38-7271 in animals needed...